2014
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke
Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, Patel NA, Pioquinto DJ, Unger T, Katovich MJ, Steckelings UM, Sumners C. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 2014, 81: 134-141. PMID: 24508710, PMCID: PMC7472595, DOI: 10.1016/j.neuropharm.2014.01.044.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 2 Receptor BlockersAnimalsBrain InfarctionBrain IschemiaCD11b AntigenCerebrovascular CirculationCytokinesDisease Models, AnimalDose-Response Relationship, DrugEndothelin-1Glial Fibrillary Acidic ProteinImidazolesMaleNitric Oxide Synthase Type IIPeroxidasePyridinesRatsRats, Sprague-DawleyStrokeSulfonamidesThiophenesTime FactorsConceptsMiddle cerebral artery occlusionPost-stroke administrationEndothelin-1Neurological deficitsIschemic strokeCerebroprotective actionCerebral damageCerebral ischemiaAT2R agonistChemokine (C-C) motif ligand 2Inducible nitric oxide synthaseBeneficial effectsCerebral infarct sizeMCAO-induced increaseCerebral artery occlusionAnti-inflammatory effectsCerebral blood flowNitric oxide synthaseSelective AT2R agonistPotential therapeutic valueType 2 mRNAAT2R inhibitorArtery occlusionPeripheral administrationHemorrhagic stroke
2013
Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke
Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, Sumners C. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013, 71: 154-163. PMID: 23583926, PMCID: PMC3664115, DOI: 10.1016/j.neuropharm.2013.03.025.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IAnimalsAnti-Inflammatory Agents, Non-SteroidalBrain IschemiaCells, CulturedCerebral CortexDisease Models, AnimalGene Expression RegulationMaleMiceMice, Inbred StrainsMice, KnockoutMicrogliaNerve Tissue ProteinsNeuroprotective AgentsNitric OxideNitric Oxide Synthase Type IIPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledSpecific Pathogen-Free OrganismsStrokeConceptsInducible nitric oxide synthaseAnti-inflammatory effectsIschemic strokeEndothelin-1Cerebral cortexMiddle cerebral artery occlusionCerebral infarct sizeDifferentiation molecule 11bIntracerebral inflammatory responseCerebral artery occlusionAnti-inflammatory actionLipopolysaccharide-induced increasePro-inflammatory cytokinesCerebral blood flowINOS protein expressionNitric oxide synthaseNitric oxide productionNitric oxide generationExpression of mRNAAng-(1-7) treatmentSignificant cerebroprotectionCerebral vasoconstrictionArtery occlusionCerebroprotective actionReceptor MasUtilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion
Regenhardt R, Ansari S, Azari H, Caldwell K, Mecca A. Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion. Journal Of Visualized Experiments 2013 DOI: 10.3791/50015-v.Peer-Reviewed Original ResearchUtilizing a cranial window to visualize the middle cerebral artery during endothelin-1 induced middle cerebral artery occlusion.
Regenhardt RW, Ansari S, Azari H, Caldwell KJ, Mecca AP. Utilizing a cranial window to visualize the middle cerebral artery during endothelin-1 induced middle cerebral artery occlusion. Journal Of Visualized Experiments 2013, e50015. PMID: 23463164, PMCID: PMC3605805, DOI: 10.3791/50015.Peer-Reviewed Original ResearchConceptsCranial windowEndothelin-1Cerebral arteryBrain parenchymaMiddle cerebral artery occlusion modelMiddle cerebral artery occlusionCerebral artery occlusionArtery occlusion modelMiddle cerebral arteryArtery occlusionIschemic strokeVasoconstricting peptideOcclusion modelVisualized vesselsLateral aspectTemporal boneArteryProximal portionRat cerebrumDuraVessel diameterCortical surfaceMCAOParietal boneParenchyma
2011
Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke
Mecca AP, Regenhardt RW, O’Connor T, Joseph JP, Raizada MK, Katovich MJ, Sumners C. Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2011, 96: 1084-1096. PMID: 21685445, PMCID: PMC3210510, DOI: 10.1113/expphysiol.2011.058578.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IAngiotensin IIAngiotensin-Converting Enzyme 2AnimalsDiminazeneEndothelin-1Enzyme ActivationInfarction, Middle Cerebral ArteryMaleNitric Oxide Synthase Type IIPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasProto-Oncogene ProteinsRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledStrokeConceptsMiddle cerebral artery occlusionIschemic strokeDiminazine aceturateNeurological deficitsBeneficial actionsInducible nitric oxide synthase (iNOS) expressionInducible nitric oxide synthase (iNOS) mRNA expressionNitric oxide synthase mRNA expressionNitric oxide synthase expressionCerebral infarct sizeCerebral artery occlusionCerebral ischemic strokeOxide synthase expressionCerebral blood flowExert beneficial actionsType 1 receptorActivation of angiotensinSynthase mRNA expressionACE2 activatorACE2-AngCerebroprotective propertiesDIZE treatmentCerebral infarctsProduction of angiotensinArtery occlusionCentral and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic Stroke
Joseph J, Regenhardt R, Mecca A, Patel N, Steckelings U, Unger T, Katovich M, Sumners C. Central and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic Stroke. The FASEB Journal 2011, 25: lb576-lb576. DOI: 10.1096/fasebj.25.1_supplement.lb576.Peer-Reviewed Original ResearchMiddle cerebral artery occlusionIpsilateral gray matterArtificial cerebrospinal fluidInfarct sizeMCAO inductionIschemic strokeNeurological deficitsControl ratsAdult male Sprague-Dawley ratsAngiotensin type 2 receptorGray matterMale Sprague-Dawley ratsSpecific AT2R agonistCerebral artery occlusionExert beneficial actionsSprague-Dawley ratsType 2 receptorACSF controlsCerebroprotective effectArtery occlusionPeripheral administrationAT2R agonistIP administrationEndothelin-1Intracerebroventricular infusion
2010
Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizures
Cao W, Glushakov A, Shah HP, Mecca AP, Sumners C, Shi P, Seubert CN, Martynyuk AE. Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizures. Amino Acids 2010, 40: 1151-1158. PMID: 20839013, PMCID: PMC8396070, DOI: 10.1007/s00726-010-0739-4.Peer-Reviewed Original ResearchConceptsMiddle cerebral artery occlusionET-1 administrationInfarct volumePTZ administrationEndothelin-1Cardiovascular parametersOnset of MCAOCerebral artery occlusionArterial blood pressureCaspase-3-positive cellsSpontaneous locomotor activityNovel therapeutic directionArtery occlusionExperimental strokeNeurological deficitsBlood pressureSeizure scoreNeurological functionIntracerebral injectionIntraperitoneal injectionBolus injectionRat modelHeart rateControl animalsPositive cells
2009
Candesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusion
Mecca AP, O'Connor TE, Katovich MJ, Sumners C. Candesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusion. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2009, 94: 937-946. PMID: 19429641, PMCID: PMC2742297, DOI: 10.1113/expphysiol.2009.047936.Peer-Reviewed Original ResearchConceptsAng II type 1 receptor blockerIschemic strokeEndothelin-1-induced middle cerebral artery occlusionMiddle cerebral artery occlusion modelBrain renin-angiotensin systemType 1 receptor blockerMiddle cerebral artery occlusionIpsilateral gray matterCerebral artery occlusionRenin-angiotensin systemArtery occlusion modelAnimal stroke modelsSignificant neurological impairmentCandesartan pretreatmentCerebroprotective propertiesGradual reperfusionEmbolic strokeArtery occlusionNeurological deficitsReceptor blockersSystemic pretreatmentBlood pressureCerebral ischaemiaMCAO modelInfarct sizeCerebroprotective action of angiotensin 1‐7 in a rat model of ischemic stroke
Mecca A, O'Connor T, Dooies K, Katovich M, Sumners C. Cerebroprotective action of angiotensin 1‐7 in a rat model of ischemic stroke. The FASEB Journal 2009, 23: 947.1-947.1. DOI: 10.1096/fasebj.23.1_supplement.947.1.Peer-Reviewed Original ResearchMiddle cerebral artery occlusionAngiotensin-Converting Enzyme 2Ang-1Artificial cerebrospinal fluidControl ratsIschemic strokeNeurological deficitsInfarct sizeAngiotensin 1Rat modelArtificial cerebrospinal fluid controlsIpsilateral gray matterCerebral artery occlusionLateral ventricular cannulasConverting enzyme 2Cerebrospinal fluid controlsCerebroprotective propertiesMCAO inductionArtery occlusionCerebroprotective actionEndothelin-1Ventricular cannulaEnzyme 2Cerebrospinal fluidET-1